☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Breakthrough Therapy designation
Genentech's Gantenerumab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Alzheimer's Disease
October 11, 2021
Hutchmed's Amdizalisib (HMPL-689) Receives Breakthrough Therapy Designation for the Treatment of R/R Follicular Lymphoma in China
September 13, 2021
Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) Receive the US FDA's Breakthrough Therapy Designation for the Treat...
September 10, 2021
Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma
August 13, 2021
Takeda's TAK-994 Receives Breakthrough Therapy Designation for the Treatment of Narcolepsy Type 1
July 29, 2021
Genentech's Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Sy...
July 21, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.